Summary of findings 4. 5‐FU/cisplatin/anthracycline combinations versus 5‐FU/anthracycline combinations (without cisplatin) for advanced gastric cancer.
| 5‐FU/cisplatin/anthracycline combinations versus 5‐FU/anthracycline combinations (without cisplatin) for advanced gastric cancer | ||||||
|
Patient or population: people with advanced gastric cancer
Settings: outpatient clinics participating in international multicentre studies
Intervention: 5‐FU/cisplatin/anthracycline combinations Control: 5‐FU/cisplatin combinations (without anthracyclines) | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| 5‐FU/anthracycline combinations (without cisplatin) | 5‐FU/cisplatin/anthracycline combinations | |||||
| Overall survival | Study population | HR 0.82 (0.73 to 0.92) | 1147 (7) | ⊕⊕⊝⊝ low1,2 | Weighted average of median survival durations from included studies | |
| 6.2 months | 8.4 months | |||||
| *For time‐to‐event outcomes, e.g. overall survival, the assumed and corresponding risks were obtained by calculating the weighted average of the median survival durations reported in included studies. For dichotomous outcomes, the assumed and corresponding risks (and their 95% confidence interval) are based on proportions of events in the control and intervention groups respectively. CI: Confidence interval; HR: Hazard ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Downgraded by one level for risk of bias. 2 Downgraded by one level for statistical heterogeneity.
Several critical outcomes (i.e. tumour response, progression‐free survival, treatment‐related death and discontinuation due to toxicity) were not evaluated or reported in a consistent fashion in these studies, most of which were conducted before year 2000.